| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7964648 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Oct, 2028
(4 years from now) | |
| US8097655 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Oct, 2028
(4 years from now) | |
| US8415395 | TAKEDA PHARMS USA | Colchicine compositions and methods |
Oct, 2028
(4 years from now) | |
| US8415396 | TAKEDA PHARMS USA | Colchine compositions and methods |
Oct, 2028
(4 years from now) | |
| US8093296 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Oct, 2028
(4 years from now) | |
| US7964647 | TAKEDA PHARMS USA | Colchicine compositions and methods |
Oct, 2028
(4 years from now) | |
| US7981938 | TAKEDA PHARMS USA | Colchicine compositions and methods |
Oct, 2028
(4 years from now) | |
| US8093298 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Oct, 2028
(4 years from now) | |
| US8093297 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Oct, 2028
(4 years from now) | |
| US7619004 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Dec, 2028
(4 years from now) | |
| US7935731 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Dec, 2028
(4 years from now) | |
| US7601758 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares |
Feb, 2029
(4 years from now) | |
| US7915269 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Feb, 2029
(4 years from now) | |
| US7906519 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Feb, 2029
(4 years from now) | |
| US7820681 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Feb, 2029
(4 years from now) | |
| US8440721 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Feb, 2029
(4 years from now) | |
| US8440722 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Feb, 2029
(4 years from now) | |
Colcrys is owned by Takeda Pharms Usa.
Colcrys contains Colchicine.
Colcrys has a total of 17 drug patents out of which 0 drug patents have expired.
Colcrys was authorised for market use on 29 July, 2009.
Colcrys is available in tablet;oral dosage forms.
Colcrys can be used as for the treatment and prophylaxis of gout flares & the treatment of familial mediterranean fever, a method for treatment of gout flares during prophylaxis, method of treating gout flares, method of using colchicine for the prophylaxis of gout flares, method of administering colchicine to familial mediterranean fever patients.
The generics of Colcrys are possible to be released after 17 February, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 29, 2016 |
| New Indication(I-603) | Jul 30, 2012 |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 29 July, 2009
Treatment: For the treatment and prophylaxis of gout flares & the treatment of familial mediterranean fever; Method of using colchicine for the prophylaxis of gout flares; Method of treating gout flares; A metho...
Dosage: TABLET;ORAL
COLCRYS family patents
